Oral Antivirals for the Acute Treatment of Recurrent Herpes Labialis

Annals of Pharmacotherapy

Volumn 38, Issue 4, 2004, Pages 705-709

  Jensen, Lori A ^a   Hoehns, James D ^a,b   Squires, Cindy L ^b,c  

^a UNIVERSITY OF IOWA   (United States)

^b NE Iowa Family Practice Center ^*  (United States)

^c Affiliates of Family Practice   (United States)

Author keywords

Acyclovir; Cold sores; Famciclovir; Herpes labialis; Herpes simplex virus; Oral antivirals; Valacyclovir

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; FAMCICLOVIR; VALACICLOVIR;

DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; HEADACHE; HERPES LABIALIS; HERPES SIMPLEX VIRUS 1; HUMAN; NAUSEA; PAIN; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

2-AMINOPURINE; ACYCLOVIR; ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CLINICAL TRIALS; HERPES LABIALIS; HUMANS; RECURRENCE; VALINE;

EID: 1542533928     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D285     Document Type: Review

References (22)

1. Poland JM. Current therapeutic management of recurrent herpes labialis. Gen Dentistry 1994;42:46-50.
2. Embil JA, Stephens RG, Manuel FR. Prevalence of recurrent herpes labialis and aphthous ulcers among young adults on six continents. Can Med Assoc J 1975;113:627-30.
3. Rooney JF, Straus SE, Mannix ML, Wohlenberg CR, Alling DW, Dumois JA, et al. Oral acyclovir to suppress frequently recurrent herpes labialis: a double-blind, placebo-controlled trial. Ann Intern Med 1993;118:268-72.
4. Spruance SL, Hamill ML, Hoge WS, Davis LG, Mills J. Acyclovir prevents reactivation of herpes simplex labialis in skiers. JAMA 1988;260:1597-9.
5. Habif TP. Herpes simplex. In: Baxter S, ed. Clinical dermatology: a color guide to diagnosis and therapy. 3rd ed. St. Louis. Mosby-Year Book, 1996:325-44.
6. Corey L. Herpes simplex virus. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 5th ed. Philadelphia. Churchill Livingstone, 1998:1564-80.
7. Spruance SL, Wenerstrom G. Pathogenesis of recurrent herpes simplex labialis. IV. Maturation of lesions within 8 hours after onset and implication for antiviral treatment. Oral Surg 1984;58:667-71.
8. Bader C, Crumpacker CS, Schnipper LE, Ransil B, Clark JE, Arndt K, et al. The natural history of recurrent facial-oral infection with herpes simplex virus. J Infect Dis 1978;138:897-905.
9. Spruance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob Agents Chemother 2002;46:2238-43.
10. Spruance SL, Rea TL, Thoming C, Tucker R, Saltzman R, Boon R. Penciclovir cream for the treatment of herpes simplex labialis: a randomized, multicenter, double-blind, placebo-controlled trial. JAMA 1997;277:1374-9.
11. Raborn GW, McGaw WT, Grace M, Tyrrell LD, Samuels SM. Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study. J Am Dent Assoc 1987;115:38-42.
12. Spruance SL, Stewart JC, Rowe NH, McKeough MB, Wenerstrom G, Freeman DJ. Treatment of recurrent herpes simplex labialis with oral acyclovir. J Infect Dis 1990;161:185-90.
13. Spruance SL, Rowe NH, Raborn GW, Thibodeau EA, D'Ambrosio JA, Bernstein DI. Perioral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: a double-blind, dose-ranging, placebo-controlled, multicenter trial. J Infect Dis 1999;179:303-10.
14. Spruance SL, Jone TM, Blatter MM, Vargas-Cortes M, Barber J, Hill J, et al. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother 2003;47:1072-80.
15. Laiskonis A, Thune T, Neldam S, Hiltunen-Back E. Valacyclovir in the treatment of facial herpes simplex virus infection. J Infect Dis 2002;186(suppl 1):S66-70.
16. Chosidow O, Drouault Y, Garraffo R, Veyssier P. Valacyclovir as a single dose during prodrome of herpes facialis: a pilot randomized double-blind clinical trial. Br J Dermatol 2003;148:142-6.
17. Drug prices and information. www.drugstore.com (accessed 2004 Feb 4).
18. Package insert. Zovirax (acyclovir). Research Triangle Park, NC: Glaxo Smith Kline, August 2002.
19. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998;26:541-55.
20. Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, Miranda P, et al. Pharmacokinetics of the acyclovir prodrug valaciclovir after escalating single and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;73:110-6.
21. Package insert. Valtrex (valacyclovir). Research Triangle Park, NC: Glaxo Smith Kline, August 2002.
22. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valacyclovir, the 1-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 1995;39:2759-64.